GSK3B and renal cell carcinoma: On the other hand, PRR11 activates the AKT signaling pathway, which in turn inhibits GSK3β activity, thereby preventing PRR11 degradation, forming a positive feedback loop and accelerating RCC progression (Figure 8J).